Numeric Investors Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Numeric Investors reduced its stake in Amgen by 25.55% during the most recent quarter end. The investment management company now holds a total of 1,206,476 shares of Amgen which is valued at $176,652,216 after selling 414,020 shares in Amgen , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Amgen makes up approximately 1.79% of Numeric Investors’s portfolio.

Other Hedge Funds, Including , Nexthera Capital Lp sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 30,000 shares of AMGN which is valued $4,392,600.Violich Capital Management reduced its stake in AMGN by selling 250 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 30,220 shares of AMGN which is valued at $4,206,926. Amgen makes up approx 1.50% of Violich Capital Management’s portfolio.United States Steel Carnegie Pension Fund reduced its stake in AMGN by selling 115,796 shares or 18.32% in the most recent quarter. The Hedge Fund company now holds 516,412 shares of AMGN which is valued at $69,922,185. Amgen makes up approx 2.11% of United States Steel Carnegie Pension Fund’s portfolio.Winslow Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 64,014 additional shares and now holds a total of 1,488,379 shares of Amgen which is valued at $206,438,167. Amgen makes up approx 0.90% of Winslow Capital Management’s portfolio.Cribstone Capital Management reduced its stake in AMGN by selling 55 shares or 4.81% in the most recent quarter. The Hedge Fund company now holds 1,088 shares of AMGN which is valued at $175,712. Amgen makes up approx 0.11% of Cribstone Capital Management’s portfolio.

Amgen closed down -2.13 points or -1.45% at $145.23 with 37,64,649 shares getting traded on Monday. Post opening the session at $147.05, the shares hit an intraday low of $144.9 and an intraday high of $148.35 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $3.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $2.79. The company had revenue of $5811.00 million for the quarter, compared to analysts expectations of $5702.65 million. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.72 EPS.

Many Wall Street Analysts have commented on Amgen. Mizuho Initiated Amgen on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $164.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.